ACE-031 is a recombinant therapeutic protein, not a synthetic peptide in the traditional sense. Its structure consists of the extracellular domain of the human activin receptor type IIB (ACVR2B) fused to the Fc region of human IgG1. This design serves two purposes.

First, the ACVR2B extracellular domain acts as a decoy receptor. It binds circulating myostatin (GDF-8) and activin A with high affinity, preventing these ligands from activating the native ActRIIB receptors on muscle cells. With less inhibitory signaling, downstream pathways that suppress muscle protein synthesis are reduced, shifting the balance toward muscle growth.

Second, the IgG1 Fc region extends half-life from hours to days by reducing renal clearance and protecting against proteolytic degradation. In clinical studies, mean half-life was 10 to 15 days. This sustained circulation means a single dose can produce effects that persist for weeks.

ACE-031 operates through competitive inhibition at the ligand level. Myostatin and activin A are members of the TGF-beta superfamily that signal through heteromeric receptor complexes on muscle cells. When these ligands bind to ActRIIB on the muscle cell surface, they trigger the Smad2/3 pathway, which suppresses muscle protein synthesis and promotes protein degradation.

ACE-031 circulates in the bloodstream and binds myostatin and activin A before they reach muscle cells. This sequestration prevents receptor activation and removes the negative regulation of muscle growth. The effect is dose-dependent: as ACE-031 concentration increases, more ligand is trapped, until all available myostatin is sequestered and a plateau is reached.

Critically, ACE-031 also binds BMP9 and BMP10, ligands involved in vascular remodeling. This off-target binding explains the bleeding side effects observed in clinical trials and is why development was halted despite impressive muscle data.

The foundational evidence for ACE-031 comes from a double-blind, placebo-controlled Phase 1 study in 48 healthy postmenopausal women. Participants received a single subcutaneous dose ranging from 0.02 to 3 mg/kg.

These changes occurred from a single injection. No exercise protocol. No dietary intervention. The muscle growth was driven entirely by removing myostatin-mediated inhibition.

This study demonstrated that ACE-031 produces both muscle hypertrophy and functional strength gains in non-human primates, supporting translational relevance for human myopathies.

These bone effects were unique to ACE-031 compared to myostatin-only inhibitors. The dual inhibition of myostatin and activin A appears necessary for the full osteogenic response.

In Duchenne muscular dystrophy mouse models, ACE-031 reduced muscle damage, preserved function, and increased lean body mass. In cancer cachexia models, activation of the ERK1/2 pathway by ACE-031 prevented muscle fiber atrophy from apoptosis and improved mitochondrial metabolism.

However, the Phase 2 DMD trial in ambulant boys was terminated prematurely due to safety concerns. This underscores the importance of understanding both efficacy and risk in research design.

ACE-031 was generally well-tolerated in Phase 1 healthy volunteers. Adverse events included injection site erythema, headache, and mild systemic effects.

These effects led to termination of the Phase 2 DMD trial after the second dosing regimen.

The bleeding is not random toxicity. It is mechanistically linked to ACE-031’s off-target binding of BMP9 and BMP10, ligands critical for vascular remodeling and endothelial integrity. By sequestering these ligands, ACE-031 disrupts normal vascular maintenance, leading to fragile capillaries and bleeding diathesis.

ACE-031 has more impressive human muscle data but carries documented vascular risks. Follistatin 344 has a different mechanism with potentially better safety margins but less clinical validation. Neither is approved for human use.

The Phase 1 trial used single ascending doses from 0.02 to 3 mg/kg subcutaneously. The 3 mg/kg dose produced the most significant muscle effects.

The 2025 Reichel quality study found that commercial products labeled “ACE-031” often contained full-length ACVR2B rather than the engineered ACVR2B-Fc fusion protein. This substitution produces different pharmacokinetics, shorter half-life, and potentially different safety profiles. Our batch-specific HPLC and mass spectrometry documentation confirms the correct fusion construct and verifies against published clinical reference data. Every COA is lot-specific and downloadable before purchase.